Mavens Is Acquired by Komodo Health

January 11, 2021

Mavens, a leader in cloud-based technology solutions, has been acquired by Komodo Health.

Mavens brings together Komodo’s Healthcare Map™ and software suite with enterprise applications from Mavens, creating the most advanced data-driven, enterprise platform for healthcare and life sciences.

This deal will enable customers to more efficiently and seamlessly put life-saving therapies into the hands of patients who need them most. Deal terms were not disclosed.

“This acquisition disrupts the status quo, unlocking a fundamentally different opportunity for life sciences companies to gain access to differentiated insights through technology,” said Arif Nathoo, MD, CEO and co-founder of Komodo Health. “Purchasing fragmented and costly data assets, custom solutions and expensive consulting projects will be a thing of the past as Komodo Health delivers a seamless, data-driven platform across R&D, Commercial, Medical Affairs and Patient workflows.”

“Customers will benefit from our cloud-based enterprise platform that offers access to a suite of software solutions powered by our industry-leading Healthcare Map,” added Web Sun, President and co-founder of Komodo Health. “This will revolutionize the value that healthcare and life sciences companies can now realize.”

“We are excited to join forces with Komodo Health to create a next-generation solution for the industry,” said Prasad Kanumury (PK), founder and CEO of Mavens. “Together, we will transform the way life sciences companies support patients and providers, ultimately reducing the burden of disease across the globe. This raises the bar and changes the expectations of the entire healthcare ecosystem.”

Together, Komodo and Mavens will expand their software capabilities, powered by insights from Komodo’s Healthcare Map™ — which tracks more than 320 million de-identified patient journeys. As the industry shifts toward a patient-centered data model, enterprise healthcare companies can end their reliance on legacy data aggregators. The acquisition will also accelerate Komodo’s global expansion, as Mavens currently operates in the U.S., U.K. and India.

The acquisition of Mavens also comes on the heels of continued financial investment in Komodo Health, which raised $44 million in Series D funding led by ICONIQ Growth. Previous investors Andreessen Horowitz, Oak HC/FT, IA Ventures, Felicis Ventures, and McKesson Ventures all participated in the round. This funding will accelerate Komodo Health’s ability to expand its Healthcare Map, platform, and solutions and further accelerate its mission to reduce the global burden of disease.

“We have long admired Komodo’s achievements and we believe the company’s unique approach has finally linked robust patient journey data with crucial workflows to achieve greater efficiency and better outcomes in healthcare,” said Caroline Xie, General Partner, ICONIQ Growth. “With the acquisition of Mavens, Komodo extends its strategy deeper into the life sciences enterprise and remains well capitalized to accelerate its impact across the entire healthcare ecosystem.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version